tbuckley/cabot-search huggingface dataset:
P155 BLOCKING OF NEGATIVE CO-STIMULATORY PATHWAYS CAN ENHANCE TUMOR-SPECIFIC T-CELL RESPONSE IN HCC PATIENTS UNDERGOING AN IMMUNOTHERAPEUTIC PROTOCOL BASED ON RADIOFREQUENCY THERMAL ABLATION
Authors: A. Zerbini, M. Pilli, A. Olivani, C. Schianchi, E. Biasini, D. Canetti, M. Massari, F. Fagnoni, C. Ferrari, G. Missale
Journal: Journal of Hepatology (2014)
A new perspective on COPD exacerbations: monitoring impact by measuring physical, psychological and social resilience
Authors: Martijn A. Spruit, Frits M.E. Franssen, Erica P.A. Rutten, Suzan Wopereis, Emiel F.M. Wouters, Lowie E.G.W. Vanfleteren
Journal: European Respiratory Journal (2016)

In 2011, Huber et al. [1] defined health as "the ability to adapt and self-manage in the face of social, physical, and emotional challenges". This definition seems very useful to monitor or even predict the impact of exacerbations of chronic obstructive pulmonary disease (COPD), or the so-called lung attacks. Monitoring the impact of COPD exacerbations by measuring physical, psychological and social resilience <http://ow.ly/VCjRC>
FRI0485 18f-fluorodeoxyglucose positron emission tomography in elderly patients with an elevated erythrocyte sedimentation rate of unknown origin
Authors: K. D. F. Lensen, A. E. Voskuyl, C. J. van der Laken, E. F. I. Comans, D. van Schaardenburg, A. B. Arntzenius, T. Zwijnenburg, F. Stam, M. Gompelman, F. van der Zant, A. Q. van Paassen, B. Voerman, F. Smit, S. Anten, C. E. Siegert, A. Binnerts, Y. M. Smulders
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Patients with an elevated erythrocyte sedimentation rate (ESR) and non-specific symptoms often pose a diagnostic dilemma. PET/CT visualises infection, inflammation and malignancy, all of which may cause elevated ESR. <h3>Objectives</h3> To determine the contribution of 18F-fluorodeoxglucose positron emission tomography (PET/CT) in the diagnostic work-up of referred patients with an elevated ESR, in whom initial routine evaluation did not reveal a diagnosis, in order to detect large vessel vasculitis, among other diseases. <h3>Methods</h3> In a combined retrospective (A) and prospective (B) study PET/CT was performed in elderly patients (&gt; 50 years of age) who presented with a significantly elevated ESR (≥ 50 mm/h) and non-specific complaints. In addition, a protocolised work-up (including chest X-ray, abdominal ultrasound and protein electrophoresis) was used in study B. In both studies, the final diagnosis was based on histology, clinical follow-up, response to therapy and/or additional imaging. <h3>Results</h3> In study A, 30 patients were included. PET/CT results suggested malignancy (8 patients), inflammatory disease (8 patients, including 5 with large-vessel vasculitis) and infection (3 patients). In 2 patients, non-specific abnormalities were found. Of the 21 patients with abnormal PET/CT results, final diagnoses were in accordance with PET/CT results in 12 patients (including 5 with large-vessel vasculitis). In 9 patients, abnormalities detected by PET/CT did not contribute to the final diagnosis. Two diagnoses (tendinitis and acute myeloid leukaemia) were established in 9 patients with a normal scan. In study B, 58 patients were included. PET/CT results suggested inflammatory disease (25 patients), particularly large-vessel vasculitis (14 cases), infection (5 patients) and malignancy (3 patients). 7 scans demonstrated non-specific abnormalities. Of the 40 patients with abnormal PET/CT results, final diagnoses were in accordance with PET/CT results in 22 patients (including 14 with large-vessel vasculitis). In 18 patients PET/CT abnormalities did not contribute to a final diagnosis. One final diagnosis (PMR) was established in 20 patients with a normal scan. <h3>Conclusions</h3> PET/CT may be of potential value in the diagnostic work-up of patients with non-specific complaints and an elevated ESR. In particular, large-vessel vasculitis appears to be a common finding. A normal PET/CT scan in these patients suggests that it is safe to follow a wait-and-see policy. <h3>Disclosure of Interest</h3> None Declared
Natural History of Familial Medullary Thyroid Carcinoma
Authors: Kathleen Graze, Ira J. Spiler, Armen H. Tashjian, Kenneth E. W. Melvin, Sergio Cervi-Skinner, Robert F. Gagel, Harry H. Miller, Hubert J. Wolfe, Ronald A. DeLellis, Lucian Leape, Zoila T. Feldman, Seymour Reichlin
Journal: New England Journal of Medicine (1978)

To detect familial medullary thyroid carcinoma in a premetastatic stage, we administered tests provocative of calcitonin secretion (infusion of calcium or pentagastrin or both) each year for seven years to members of a pedigree now numbering 107. Since 1970, 21 patients converted from normal to abnormal secretory responses (two separate tests in which calcitonin levels exceeded 0.58 ng per milliliter). Twenty of 21 glands removed showed C-cell hyperplasia, and eight of the 20 also showed foci of carcinoma. As compared to the 12 patients with tumors detected during the first year of screening, all of whom had bilateral carcinoma (seven of 12 with local metastases), later carcinomas were smaller (mean diameter of 0.2 vs. 0.8 cm), were unilateral (in all but two cases) and occurred in younger patients (mean age of 14.9 vs. 36.4 years), and none had detectable metastases. (N Engl J Med 299:980–985, 1978)
SP0020 Risk Factors for RA: GENE Environment Interactions
Authors: S. Rantapää Dahlqvist
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation in the joints involving the synovial tissue and ultimately leading to the destruction of cartilage and bone. The aetio-pathogenic processes leading to the development of the disease are not fully understood. We and others have shown that antibodies against citrullinated proteins/peptides (ACPA), detectable as anti-CCP2 antibodies of the IgG, IgA and IgM isotype, precede the development of RA by several years. Increased levels of pro-inflammatory cytokines and chemokines suggest ongoing inflammation years before onset of symptoms in some individuals who subsequently develop RA. The fluorescence intensity of antibodies against citrullinated peptides, fibrinogen (Fib)ß36–52, Fibß74, CEP-1, citC1<sup>III</sup>, and filaggrin were significantly increased in pre-disease individuals compared with controls. Antibodies against Fibß36-52, CEP-1 and filaggrin increased gradually reaching the highest levels of all antibodies before symptom onset. The levels of the earliest detectable antibodies (Fibα591 and vimentin (Vim)60-75) increased only slightly before onset of symptoms, although more after onset of disease. A cluster of antibodies, citC1<sup>III</sup>, Fibα573 and Fibß74 increased only slightly before onset of symptoms but prominently after disease onset. The odds ratio for development of RA with a combination of CEP-1 and Fibß36-52 antibodies (&lt;3.35 years pre-dating) was 38.8 (CI 95%14.5-103.5) compared with having either. Besides these antibodies the development was also predicted by presence of HLA-shared epitope and smoking independently. The combinaions of HLA-shared spitope, smoking and any of the three most frequently occuring antibodies and anti-CCP were highly associated with disease develoment compared with not having any of these factors. Disease development was also associed with socio-economic and life stile factors e.g. lower education and manual work increased the risk. There were no impact on disease development by cost or alcholhol intake. Presence of antibodies against citrullinated peptides (Fibß36-52, fillagrin, CEP-1, CCP) was associated with smoking habits, HLA-shared epitope, particularly 0401 and PTPN22 independently for each factor and without demonstrable interactions <h3>Disclosure of Interest</h3> None Declared
Lost in Translation — ¿<i>Cómo se dice,</i> “Patient Protection and Affordable Care Act”?
Authors: James O. Breen
Journal: New England Journal of Medicine (2012)

Interview with Dr. Francesca Gany on undocumented immigrants and the U.S. health care system. (17:25)Download For the roughly 11 million undocumented persons living in the United States, the Affordable Care Act will make it more difficult to gain access to basic primary care service, as the newly insured strain the health care infrastructure and charity care is reduced.
Identification of three-genomic regions prognostic signature in small node-negative breast carcinomas.
Authors: E Gravier, G Pierron, A Vincent-Salomon, A Savignoni, N Gruel, V Raynal, J Pierga, A Fourquet, F Reyal, S Roman-Roman, X Sastre-Garau, Y de Rycke, B Asselain, O Delattre
Journal: Cancer Research (2009)

Abstract Abstract #1081 Background: The purpose of this study was to identify a genomic signature of early metastatic recurrence, in order to predict accurately breast carcinomas clinical outcome and to select patients with node negative and small tumor size (&amp;lt;3cm) who would benefit from adjuvant chemotherapy.&amp;#x2028; Patients and methods: Using genome-wide BAC-PAC Genomic Comparative Hybridization (CGH) array (1kb), we analyzed a training set of 78 patients. All patients had invasive ductal carcinomas and were initially treated by surgery and radiotherapy, without chemotherapy. The validation was performed on an independent test set of 90 patients. The training and tests sets were composed of respectively 53 and 58 patients disease-free survivors at 60 months (good prognosis group), and by 25 and 32 patients with distant metastatic recurrence before 48 months (poor prognosis group). In the training set, a signature was established as a logistic multivariate model of regions containing contiguous BAC clones with statistically different ratios and median frequencies of gains and losses between the poor and the good prognosis groups. This signature was then validated using the independent test set to evaluate its accuracy to classify T0T1T2N0 patients according to their outcome.&amp;#x2028; Results: The training test identified a prognostic signature defined by 3 genomic regions, located on the 2p (38.3 to 40.9Mb), 3p (32 to 80.3Mb), and 8q (78.8 to 128.9Mb) chromosomes. In the test set, 90% of patients of favourable outcome were ER +ve and 88% were PR +ve, compared to 62% and 55% in the poor outcome group, respectively. In the test set, our signature was highly informative to identify patients that developed distant metastases before 48 months: the rate of patients well classified was 0.74, CI (95%): [0.64; 0.83], with a specificity of 95%, CI (95%): [86%; 99%]. On Kaplan-Meier analysis, the poor-prognosis genomic signature group of patients had a RR of 3.5 of metastatic relapse (log rank test p&amp;lt;0.001).&amp;#x2028; Conclusions: Our signature, validated on an independent series of small T0T1T2N0 and on a majority of ER/PR positive tumors, may provide a robust and accurate tool to identify, in addition to classical parameters, patients who would benefit from adjuvant medical treatments. The comparison of this genomic signature with RNA based signatures and clinico-pathological parameters, is currently being investigated. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1081.
Gwynneth June Davey
Authors: G. Cooper
Journal: BMJ (2011)

This method was developed to demonstrate the application of probabilistic bias analysis to quantify and adjust for exposure misclassification in a historical cohort mortality study of New Zealand trichlorophenol workers where exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was measured as a multi-level variable. Published exposure information available for this cohort of workers was used to specify the initial bias parameter distributions, which were then varied under 18 different scenarios to assess the potential impact of differing amounts of misclassification as well as both non-differential and differential exposure misclassification. For each scenario, each bias parameter distribution was sampled 50 000 times using Monte Carlo simulation techniques to generate adjusted counts of cases and non-cases of ischemic heart disease (IHD) by exposure group. These counts were then used to calculate odds ratios adjusted for exposure misclassification and the associated exposure misclassification error terms. Given the specified assumptions, the geometric mean (GM) adjusted odds ratio had a range of 2.89 to 5.05, and the GM error term ranged from 0.60 to 1.05. In all non-differential scenarios and scenarios in which non-cases had greater proportions of misclassification, the observed odds ratio of 3.05 was closer to the null (i.e., 1) than the GM adjusted odds ratio. For the differential simulations where cases had higher proportions of misclassification, the direction of the error was dependent on the level of misclassification error, with smaller proportions of misclassification resulting in the observed odds ratio being farther away from the null than the GM adjusted odds ratio. These findings demonstrate that probabilistic bias analysis of historical cohort mortality studies can be an effective tool for understanding trends in study error stemming from exposure misclassification and confirm the importance of quantifying potential sources of systematic error.
Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings
Authors: J Bradwejn, D Koszycki, R Payeur, M Bourin, H Borthwick
Journal: American Journal of Psychiatry (1992)

Eleven patients with panic disorder were challenged with cholecystokinin tetrapeptide (CCK-4) on two occasions. The effects of CCK-4 were consistent except symptom onset was more rapid with the second injection. Demonstrating that the effects of CCK-4 are reproducible in panic patients opens the doors for studies of the effects of drug treatment on CCK-4-induced panic.
SAT0379 High Prevalence of Urolithiasis in Southern Chinese Gout Patients
Authors: Q.-H. Li, H.-J. Liu, D.-H. Zheng, J.-D. Ma, C.-J. Zou, Z.-X. Li, L. Dai
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The prevalence of urolithiasis in general Chinese population was 5%&gt;10%. It has been reported as a common complication of gout in many countries (20%&gt;39.5%) but not yet in China. Urolithiasis is one of the contraindications of uricosuric drugs. However, allopurinol, the only other available urate lowering drug in China, has been confirmed high risk of allopurinol hypersensitivity syndrome in Chinese population and those with chronic kidney disease. <h3>Objectives</h3> To investigate the prevalence of urolithiasis in southern Chinese gout patients and the possible risk factors. <h3>Methods</h3> 201 hospitalized patients with primary gout were recruited and their clinical data were collected. Current urolithiasis was defined as positive image finding including ultrasound, plain film or computer tomography. Positive history of urolithiasis delivery or urolithiasis surgery but negative image finding was defined as previous urolithiasis. <h3>Results</h3> (1)Among 201 gout patients, 89.1% were male with mean age 57.5±16.9 years while 10.9% were female with mean age 68.5±11.9 years. The mean disease duration was 7.9±7.4 years with involved joints 6.4±7.4. 30.7% patients presented tophi. The average serum uric acid (sUA) was 8.9±2.7mg/dl with 24h uric acid excretion 451.9±240mg. 91.6% patients excreted uric acid lower than 800mg/24h. Serum creatinine was 133.1±84.6umol/l and estimate glomerular filtration rate (eGFR) 60.0±19.4ml/min. (2) 33.8% patients complicated with urolithiasis, of which 75.0% were current urolithiasis and 33.8% were current urolithiasis without positive urolithiasis history. 84.3% were neprolithiasis and 57.1% were multiple urolithiasis. (3)Table 1 showed significant differences of sUA, hyperuricemia, eGFR, impaired renal function and renal cyst between urolithiasis group and non-urolithaisis group. Current urolithiasis exacerbate eGFR more than previous urolithiasis (51.4±18.3ml/min VS 61.8±17.8ml/min, P=0.045). (4) Urolithiasis was significantly correlated with hyperuricemia (r=0.156, P=0.027), impaired renal function (r=0.27, P&lt;0.001) and renal cyst (r=-0.252, P&lt;0.001). Logistic regression showed that renal cyst negatively predicted the presence of urolithiasis in gout patients (OR=0.066, 95%CI 0.013-0.298, P=0.001) while eGFR&lt;60ml/min promoted urolithiasis (OR=3.786, 95%CI 1.516-9.454, P=0.004). <h3>Conclusions</h3> Our results showed high prevalence of urolithiasis in southern Chinese gout patients. Routine imaging test on urinary system should be performed to detected urolithiasis in all gout patients especially for those with renal impairment. <h3>Disclosure of Interest</h3> None Declared
Biased assessment of 3D optical coherence tomography in a single post-radiofrequency ablation patient without histological correlation
Authors: R. Pouw, J. Bergman
Journal: Endoscopy (2010)

A case report entitled “Three-dimensional optical coherence tomography of Barrett’s esophagus and buried glands beneath neosquamous epithelium following radiofrequency ablation,” was recently published by Adler et al. in Endoscopy [1]. Based on the title and abstract, we fully expected the authors to present evidence showing that three-dimensional optical coherence tomography (3D-OCT) was able to detect buried Barrett’s after radiofrequency ablation (RFA) that was otherwise not detectable with conventional methods. Unfortunately, the authors report a single ablation-naïve case where it seems that buried glands were detected on biopsy yet not specifically detected with 3D-OCT or explicitly described in their findings, followed by a single (separate) post-ablation case where structures near the gastroesophageal junction (GEJ) imaged with 3D-OCT were deemed “buried Barrett’s glands” by the authors, yet not confirmed histologically with biopsy. In our opinion, the title of this report is misleading, and the authors’ conclusions are far-reaching and not supported by the reported findings.
Increased Risk of Renal Cell Carcinoma Among Obese Women
Authors: A Mellemgaard, H Møller, J H Olsen, O M Jensen
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Increased Risk of Renal Cell Carcinoma Among Obese Women Get access Anders Mellemgaard, Anders Mellemgaard Search for other works by this author on: Oxford Academic PubMed Google Scholar Henrik Møller, Henrik Møller Search for other works by this author on: Oxford Academic PubMed Google Scholar Jørgen H. Olsen, Jørgen H. Olsen Search for other works by this author on: Oxford Academic PubMed Google Scholar Ole Møller Jensen Ole Møller Jensen Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 21, 6 November 1991, Pages 1581–1582, https://doi.org/10.1093/jnci/83.21.1581 Published: 06 November 1991 Article history Received: 18 June 1991 Revision received: 26 July 1991 Accepted: 06 August 1991 Published: 06 November 1991
Idiopathic CD4+ T-Lymphocytopenia
Authors: Jack A. DeHovitz, Joseph Feldman, Sheldon Landesman
Journal: New England Journal of Medicine (1993)

To the Editor: Several articles and an editorial in the February 11 issue of the Journal draw the conclusion that idiopathic CD4+ T-lymphocytopenia is extremely rare1–5. However, transient CD4+ T-lymphocytopenia as a consequence of a low total white-cell count may be relatively common in some subgroups of the population. As part of a study of the heterosexual transmission of human immunodeficiency virus (HIV), we examined CD4 cells in a sample of 255 sexually active women without a history of intravenous drug use. The subjects were drawn from hospital clinics and from an area of New York (Kings County) . . .
Abstract 3811: Robust anti-tumor activity through targeting integrin α5β1 and eliciting ADCC with a dual functional monoclonal antibody PF-04605412
Authors: Dana D. Hu-Lowe, Gary Li, Enhong Chen, Jianying Wang, Lianglin Zhang, Jeffrey H. Chen, Karin Amundson, Zobel James, Eugenia Kraynov, Leslie Sharp, Grant Wickman, Xin Jiang, Steve Bender, Gerald Casperson
Journal: Cancer Research (2010)

Abstract Integrin α5β1 and its ligand fibronectin are significantly and coordinately over-expressed in tumor associated blood vessels and cancer cells. These molecules have been reported to mediate angiogenesis, tumor survival and metastasis. α5β1 has also been implicated as a poor prognostic marker in a number of human tumor types including NSCLC and ovarian carcinoma. Thus, α5β1 is a potential target for cancer therapy. Accumulating evidence suggests an important role of innate immune effector cells in tumor killing via antibody dependent cellular cytotoxicity (ADCC). Taking advantage of both of these mechanisms, we generated an α5 integrin-specific neutralizing monoclonal antibody (mAb, PF-04605412) with high affinity for Fcγ receptors. In vitro, PF-04605412 potently inhibited α5β1-mediated intracellular signaling, cell adhesion, migration, endothelial cell tubulogenesis, and induced apoptosis of endothelial and tumor cells. Compared to a wild type IgG1 of identical antigen specificity (wt IgG1), PF-04605412 induced a significantly greater tumor and endothelial cell cytotoxicity. ADCC activity correlated with the abundance of NK cells within PBMCs of human donors, but was independent of donor FcγRIIIa polymorphism. In in vivo studies using human xenograft, immuno-xenograft and syngeneic tumor models, PF-04605412 (and an anti-murine α5 surrogate mAb) displayed robust and dose-dependent anti-angiogenesis and anti-tumor efficacy including tumor growth delay, regression and metastasis inhibition, all of which were superior to effects observed with an IgG2 or wt IgG1 of identical antigen specificity. Western blotting and immunohistochemistry analysis of tumor samples showed that anti-tumor efficacy was associated with reduction of total and phosphorylated focal adhesion kinase and positively correlated with α5 expression, infiltrating macrophages, markers of effector cell activity, and apoptosis. Furthermore, depletion of host macrophages abrogated anti-tumor efficacy, indicating a critical contribution of ADCC/phagocytosis to the anti-tumor activity of PF-04605412. The PK-PD relationship, efficacy of PF-04605412 in combination with anti-angiogenic and tumor targeting agents will also be reported. The distinct dual mechanism of action and robust anti-tumor efficacy of PF-04605412 supports the clinical development of this agent for the treatment of human cancers. Short Title: Dual functional mAb PF-04605412 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3811.